# Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
Canonical URL: https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-announces-u-s-fda-approval-for-atzumitm-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine
Ticker: STSA
Company: Satsuma
Source: Satsuma
Published: 2025-05-01 00:00 EST
Original Source URL: https://investors.satsumarx.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-04 12:00 EST — [Satsuma Pharmaceuticals Announces Presentation of Two Clinical Program Abstracts at the American Headache Society's 68th Annual Scientific Meeting](https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-announces-presentation-of-two-clinical-program-abstracts-at-the-american-headache-society-s-68th-annual-scientific-meeting) — Source: Satsuma
- 2025-11-05 13:00 EST — [Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache](https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-and-snbl-announce-publication-of-impression-of-use-and-satisfaction-with-sts101-dihydroergotamine-nasal-powder-atzumitm-in-headache) — Source: Satsuma
- 2025-06-19 13:00 EST — [Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting](https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-and-snbl-announce-four-abstracts-to-be-presented-at-the-american-headache-society-s-67th-annual-scientific-meeting) — Source: Satsuma
- 2025-05-01 00:00 EST — [Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine](https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-announces-u-s-fda-approval-for-atzumitm-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine) — Source: Satsuma
- 2024-11-26 14:00 EST — [Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura](https://biopharmsignal.com/news/STSA/satsuma-pharmaceuticals-and-snbl-receive-fda-acceptance-of-nda-resubmission-of-sts101-for-the-acute-treatment-of-migraine-with-or-without-aura) — Source: Satsuma
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)